✓Sep 1 session - Last update: Sep 1, 2026, 4:56 PM ET
⚡Material / Earnings✓High confidence
Source: daily_prices:fmp_change_percent
Changes History →Market closed · Next open: Wednesday 9:30 AM ET
Last update: Sep 1, 2026, 6:08 PM ETMarket closed·123 changes confirmed today
Track the stock moves that actually matter.
BestStocks detects meaningful changes across price, volume, earnings, filings, valuation, analyst revisions, and risk signals — and shows you the evidence behind each one.
1,000 equities monitored14 signal typesCross-checked against SEC EDGARMedian detection lag ~41s
Investment research built around change detection.
Showing:
BestStocks identifies what changed across companies and sectors, explains why it matters, and helps investors spot opportunities worth investigating.
✓Sep 1 session - Last update: Sep 1, 2026, 4:52 PM ET
⚡Material / Earnings✓High confidence
What changed: TG Therapeutics, Inc. (TGTX) moved +6.14% from $52.84 to $56.09 on September 1, 2026, on volume 2.3x the 5-day average. The move was driven by unconfirmed takeover speculation from M&A blog Betaville suggesting potential interest from a larger biopharma suitor, combined with investor enthusiasm over the company's raised 2026 revenue guidance for its flagship multiple sclerosis drug Briumvi to approximately $950 million and H.C. Wainwright's reaffirmed buy rating.
Source: daily_prices:fmp_change_percent
Changes History →What's next
What to watch
Monitor TG Therapeutics' earnings scheduled for November 2, 2026 (consensus EPS estimate $0.40) for updates on Briumvi sales trajectory and any management commentary on strategic alternatives.
✓Sep 1 session - Last update: Sep 1, 2026, 4:53 PM ET
🛡Material / Earnings✓High confidence
What changed: Repligen Corporation (RGEN) moved -5.20% from $179.34 to $170.02 on September 1, 2026, after gaining nearly 25% over the preceding 30 days. The decline was driven by profit-taking following the sharp rally, digestion of its pending BioLife Solutions acquisition and mixed Q2 2026 profitability trends, and sector-wide cooling in life sciences and bioprocessing stocks after a strong summer run.
Source: daily_prices:fmp_change_percent
Changes History →What's next
What to watch
RGEN earnings scheduled for October 27, 2026, with consensus EPS estimate of $0.46.
✓Sep 1 session - Last update: Sep 1, 2026, 4:53 PM ET
🛡Material / Earnings✓High confidence
What changed: SailPoint, Inc. (SAIL) moved -6.38% from $20.54 to $19.23 on 2026-09-01. No company-specific catalyst was found. The decline reflects a broader sector-wide pullback in enterprise software and SaaS infrastructure stocks driven by investor rotation toward semiconductors and AI hardware, combined with macroeconomic pressure from rising Treasury yields ahead of key economic data releases.
Source: daily_prices:fmp_change_percent
Changes History →What's next
What to watch
SailPoint earnings report on 2026-09-08 for confirmation of guidance and any commentary on enterprise software spending trends amid current market rotation.
✓Sep 1 session - Last update: Sep 1, 2026, 4:48 PM ET
🛡Material / Earnings✓High confidence
What changed: JFrog Ltd. (FROG) moved -6.52% from $98.19 to $91.78 on September 1, 2026, following reports of significant insider selling. CTO Yoav Landman sold nearly 250,000 shares, triggering profit-taking pressure on the stock after a recent valuation run-up driven by cloud revenue growth and AI infrastructure positioning.
Source: daily_prices:fmp_change_percent
Changes History →What's next
What to watch
JFrog is scheduled to report earnings on November 5, 2026 (consensus EPS estimate $0.22), which will provide concrete data on whether cloud and AI-driven growth remains intact.
✓Sep 1 session - Last update: Sep 1, 2026, 4:48 PM ET
⚡Material / Earnings✓High confidence
What changed: Summit Therapeutics Inc. (SMMT) moved +5.83% from $13.38 to $14.16 on September 1, 2026, following publication of primary analysis results from the Phase III HARMONi trial for ivonescimab in *The Lancet Oncology*. The peer-reviewed data demonstrated significant progression-free survival benefits for ivonescimab combined with chemotherapy.
Source: daily_prices:fmp_change_percent
Changes History →What's next
What to watch
SMMT earnings are scheduled for October 19, 2026 (consensus EPS estimate: −$0.28); monitor for updates on ivonescimab regulatory milestones or next-stage trial readouts.
✓Sep 1 session - Last update: Sep 1, 2026, 4:48 PM ET
🛡Material / Earnings✓High confidence
What changed: Saia, Inc. (SAIA) moved -6.35% from $354.11 to $331.62 on September 1, 2026, amid a broader market pullback affecting logistics and industrial shares. The decline follows digestion of Q2 earnings, where despite record revenues, management's cautious commentary on wage pressures, expansion costs, and terminal ramp-ups left investors sensitive to near-term margin headwinds.
Source: daily_prices:fmp_change_percent
Changes History →What's next
What to watch
SAIA earnings scheduled for October 29, 2026 (consensus EPS estimate $3.30) will be critical to validate whether margin pressures ease or persist.
✓Sep 1 session - Last update: Sep 1, 2026, 4:45 PM ET
⚡Material / Earnings✓High confidence
What changed: BWX Technologies, Inc. (BWXT) moved +6.40% from $151.82 to $161.54 on September 1, 2026, following the U.S. Army's selection of BWXT's Advanced Nuclear Reactor (BANR) for its Janus program to supply microreactor power for U.S. bases. The move was also supported by recent institutional buying, including a $7.6 million purchase by ARK Investment Management.
Source: daily_prices:fmp_change_percent
Changes History →What's next
What to watch
BWXT will host an Investor Day on September 29, 2026, which may provide updates on the Janus program and commercial nuclear pipeline.
✓Sep 1 session - Last update: Sep 1, 2026, 5:08 PM ET
⚡Material / Earnings✓High confidence
What changed: Revolution Medicines, Inc. (RVMD) moved +2.56% from $204.64 to $209.87 on 2026-09-01. We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found. Volume remained near its 5-day average at 0.7x.
Source: daily_prices:fmp_change_percent
Changes History →What's next
What to watch
Monitor for RVMD earnings on 2026-11-04 and any update to the consensus estimate.
✓Sep 1 session - Last update: Sep 1, 2026, 4:58 PM ET
🛡Material / Earnings✓High confidence
What changed: Ultra Clean Holdings, Inc. (UCTT) moved −2.50% from $66.78 to $65.11 on 2026-09-01. We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found. The stock reached a new 30-day low on volume near its 5-day average.
Source: daily_prices:fmp_change_percent
Changes History →What's next
What to watch
Monitor for the Q3 2026 earnings report on 2026-10-27 to assess whether the price decline reflects forward guidance or valuation concerns.
✓Sep 1 session - Last update: Sep 1, 2026, 4:57 PM ET
🛡Material / Earnings✓High confidence
What changed: Morningstar, Inc. (MORN) moved -4.11% from $218.84 to $209.86 on 2026-09-01. We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found. Volume remained near its 5-day average at 1.1x.
Source: daily_prices:fmp_change_percent
Changes History →What's next
What to watch
Morningstar earnings report expected 2026-10-28 (consensus EPS estimate: $2.97).
✓Sep 1 session - Last update: Sep 1, 2026, 4:57 PM ET
🛡Material / Earnings✓High confidence
What changed: Commvault Systems, Inc. (CVLT) moved -4.10% from $134.72 to $129.20 on 2026-09-01. We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found. Trading volume was near its 5-day average at 1.1x, indicating routine activity.
Source: daily_prices:fmp_change_percent
Changes History →What's next
What to watch
Commvault is scheduled to report earnings on 2026-10-27 with consensus EPS estimate of $1.25.
Latest research
View all research →In-depth equity research from the BestStocks desk — earnings breakdowns, valuation deep dives, and sector analysis behind the changes we detect.
TechnologySeptember 1, 2026 · 8 min read
Apple (AAPL) Rises as Ternus Takes Over and the Sept. 9 iPhone Event Nears
Apple rose about 2.5% to roughly $325 on September 1, and the striking part was the company it kept: on a risk-off day driven by rising Treasury yields, Apple was one of the very few large-caps to rise — Meta also gained — while Microsoft, Nvidia and Alphabet slipped alongside the Nasdaq-100. The day carried two milestones. A long-planned leadership handover took effect: John Ternus, the hardware engineer behind the iPhone and Vision Pro, became CEO, with Tim Cook — chief executive since 2011 — moving to executive chairman; the succession was announced back in April, so this was the orderly handover, not fresh news. And Apple's September 9 event, expected to unveil the iPhone 18 Pro and a first foldable, is days away. The catch is valuation: at about 36 times earnings, after a ~40% run, the stock sits right at its average analyst target and about 6% below its late-July record — and the Street is split, with a Bernstein $370 bull case against a rare Jefferies bearish call (an Underperform near $264).
AAPLRead →
IndustrialsSeptember 1, 2026 · 8 min read
Deere (DE) Hits a Record High After a Baird Upgrade on a 2027 Ag Recovery
Deere rose about 2.6% to a record high near $676 on September 1, standing out on a day technology and semiconductors sold off. The catalyst was dated and company-specific: a day earlier, Baird's Mircea Dobre upgraded Deere to Outperform and raised his price target to $800 from $640, arguing North American crop economics improve in 2027 — corn back above breakeven, better soybean margins, tighter stocks-to-use. Baird upgraded AGCO the same day, and both farm-equipment makers rose while construction bellwether Caterpillar fell, isolating an agriculture-specific move rather than a broad machinery rally. The puzzle is the valuation: Deere trades at about 36 times trailing earnings, but that reflects an expected fiscal-2026 revenue trough (down ~10% on consensus estimates), with fiscal-2027 modeled up ~8% — the recovery the upgrade is betting on. The catch: after a ~40% run to a record, the Street is split, with 11 of 24 analysts at Hold and an average target just below the price.
DERead →
HealthcareSeptember 1, 2026 · 11 min read
McKesson (MCK) Rises as a Defensive Bid Meets a $2.25B Precision Medicine Deal
McKesson rose about 2.5% to near $907 (in the upper part of its 52-week range) on September 1, standing out as technology and semiconductors sold off. The move came amid a rotation away from technology and rate-sensitive growth, as defensive areas outperformed: with the Nasdaq-100 down more than 1%, low-beta healthcare gained, and the drug distributors were among the winners — Cardinal Health and Cencora also rose. McKesson had its own tailwinds, too. On August 25 it agreed to acquire Precision Medicine Group for about $2.25 billion, folding a clinical-research and commercialization business into its fast-growing Oncology & Multispecialty segment, and it paired that with a raised outlook and a 15% dividend increase — markers of a deliberate pivot from thin-margin drug distribution into higher-value oncology and specialty services. Even so, the stock trades at about 19 times forward earnings after growing EPS more than 50% over the past year. The catch: after a ~32% run, McKesson sits near the ~$987 average analyst target, so the valuation upside has narrowed. It is a high-quality, defensively-tilted compounder the market has already discovered.
MCKRead →
ConsumerAugust 31, 2026 · 10 min read
Burlington (BURL) Stock Falls ~5% as Q3 Outlook Overshadows Q2 Beat
Burlington Stores fell about 4.8% to around $259.76 intraday on August 31, its third straight decline since the August 27 fiscal Q2 report (down ~7.6% on the 27th and ~5.9% on the 28th). The headline looked strong — reported adjusted EPS of $2.96, roughly 35% above consensus, with margin expansion and a 15th straight quarter of double-digit EPS growth — but the market looked past it. Comparable-store sales grew just 2% (down from 5% a year earlier), revenue narrowly missed at ~$3.00 billion, and Burlington guided third-quarter margins and EPS lower as it reinvests a $55 million tariff refund into customer prices. That refund also flattered the headline beat: Burlington's cleaner adjusted EPS ex-refund was $2.37 (still +38% year over year). Even though it raised full-year EPS guidance to $11.77–$11.97, a stock at ~23x earnings could not sustain a 2% comp and softer near-term margins, and Monday's leg down came as Goldman Sachs and Deutsche Bank cut targets. The move was company-specific: off-price peers Ross Stores and TJX fell less than 1% the same day. The stock is now deeply oversold (down ~31% from its high), yet 18 analysts keep a Buy consensus and a ~$365 average target.
BURLRead →
HealthcareAugust 31, 2026 · 11 min read
Cytokinetics (CYTK) Stock Falls Despite a Positive Phase 3 Aficamten Win
Cytokinetics fell about 7.5% on Friday and another ~3% Monday (to roughly $70) even though its pivotal Phase 3 ACACIA-HCM trial of aficamten met its goals in non-obstructive hypertrophic cardiomyopathy. The full data, presented at the ESC 2026 congress, hit both primary endpoints (symptoms and exercise capacity) — but the positive topline had been known since May, the stock had nearly doubled over the year, and the details disappointed: a modest effect size, two secondary endpoints that missed significance, and reduced ejection fraction (below-50% in ~10.5% of patients versus 0.8%; a known, reversible class effect). With a supplemental FDA filing not due until Q4 2026, revenue is years off, so investors sold. CYTK underperformed a soft biotech tape. Still, the Street stayed bullish: across 22 analysts, 20 rate CYTK a buy-equivalent, with an average target near $110 (about 57% above the price). Aficamten, already sold as Myqorzo for obstructive HCM, would expand into a large new patient group if the data carries through — the debate is about the details and the timeline, not whether the drug works.
CYTKRead →
TechnologyAugust 31, 2026 · 10 min read
Pinterest (PINS) Stock Falls 6% After CFO Julia Donnelly Resigns
Pinterest fell about 6% to around $21.73 on August 31 after disclosing that CFO Julia Brau Donnelly is resigning to join a private, early-stage company. She will stay until October 30 for an orderly transition, with a finance executive named interim CFO and an external search underway; the company said the exit is not due to any disagreement. Still, losing a CFO whose tenure the CEO credited with 11 straight quarters of double-digit revenue growth rattled a stock already down ~41% over the past year and trading at just ~11x forward earnings. The move was company-specific: the same day, ad peers Snap and The Trade Desk actually rose, while Meta and Alphabet fell only modestly. Analysts are constructive but split — a Buy consensus with a ~$29 average target, yet a cluster of Holds near the price — leaving the CFO exit to reopen, rather than settle, the debate over whether Pinterest's growth story holds.
PINSRead →